ProfileGDS5678 / 1453724_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 95% 94% 95% 94% 96% 94% 93% 95% 94% 94% 92% 93% 94% 91% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.3481195
GSM967853U87-EV human glioblastoma xenograft - Control 28.2395894
GSM967854U87-EV human glioblastoma xenograft - Control 38.6828895
GSM967855U87-EV human glioblastoma xenograft - Control 48.3212894
GSM967856U87-EV human glioblastoma xenograft - Control 58.9701796
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.8040494
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.5976793
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.3374595
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.0241294
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.1168194
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.5294992
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.9578893
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.1015294
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.4858591